LifeMD, Inc.
For the period ended Sep 30, 2025. Filed Nov 17, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2025 · Filed Nov 17, 2025
LFMD$2.10-11.6%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Balance Sheets
| September 30, 2025 | December 31, 2024 | |
|---|---|---|
| ASSETS | ||
| Current Assets | ||
| Cash | $23,785,771 | $35,004,924 |
| Accounts receivable | 9,244,321 | 10,854,084 |
| Product deposit | 370,518 | 40,763 |
| Inventory | 3,432,382 | 2,797,358 |
| Other current assets | 4,252,613 | 3,672,231 |
| Total Current Assets | 41,085,605 | 52,369,360 |
| Non-current Assets | ||
| Equipment, net | 2,584,829 | 1,479,184 |
| Right of use assets, net | 5,578,992 | 6,400,596 |
| Capitalized software, net | 15,175,634 | 13,816,501 |
| Intangible assets, net | 1,558,318 | 2,030,656 |
| Total Non-current Assets | 24,897,773 | 23,726,937 |
| Total Assets | $65,983,378 | $76,096,297 |
| LIABILITIES AND STOCKHOLDERS’ EQUITY (DEFICIT) | ||
| Current Liabilities | ||
| Accounts payable | $19,554,735 | $16,009,484 |
| Accrued expenses | 22,079,805 | 22,811,763 |
| Current operating lease liabilities | 673,482 | 508,537 |
| Current portion of convertible long-term debt | - | 8,444,444 |
| Deferred revenue | 14,355,531 | 19,625,940 |
| Total Current Liabilities | 56,663,553 | 67,400,168 |
| Long-term Liabilities | ||
| Convertible long-term debt, net | - | 9,885,057 |
| Noncurrent operating lease liabilities | 5,851,673 | 6,265,192 |
| Contingent consideration | 100,000 | 100,000 |
| Total Liabilities | 62,615,226 | 83,650,417 |
| Commitments and contingencies (Note 11) | - | |
| Stockholders’ Equity (Deficit) | ||
| Series A Preferred Stock, $0.0001 par value; 1,610,000 shares authorized, 1,400,000 shares issued and outstanding, liquidation value approximately, $35.8 million as of September 30, 2025 and December 31, 2024 | 140 | 140 |
| Common Stock, $0.01 par value; 100,000,000 shares authorized, 46,686,350 and 42,293,907 shares issued, 46,583,310 and 42,190,867 outstanding as of September 30, 2025 and December 31, 2024, respectively | 466,864 | 422,939 |
| Additional paid-in capital | 248,801,209 | 230,508,339 |
| Accumulated deficit | (247,790,178) | (239,850,931) |
| Treasury stock, 103,040, at cost, as of September 30, 2025 and December 31, 2024 | (163,701) | (163,701) |
| Total LifeMD, Inc. Stockholders’ Equity (Deficit) | 1,314,334 | (9,083,214) |
| Non-controlling interest | 2,053,818 | 1,529,094 |
| Total Stockholders’ Equity (Deficit) | 3,368,152 | (7,554,120) |
| Total Liabilities and Stockholders’ Equity (Deficit) | $65,983,378 | $76,096,297 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.